Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech HOLDRs (AMEX: BBH) -- Ignore unavailable to you. Want to Upgrade?

To: Curtis E. Bemis who wrote (83)	4/14/2000 10:45:00 AM
From: bob zagorin	Respond to of 98

InformedInvestors.com Streaming Today's Oscar Gruss Investor Conference on Genomics and Bioinformatics NEW YORK, April 14 /PRNewswire/ -- Celera Genomics (NYSE: CRA), Human Genome Sciences (Nasdaq: HGSI) and Incyte Genomics (Nasdaq: INCY) are among 12 companies, seven public and five private, that are presenting their prospects to institutional investors at the inaugural Oscar Gruss & Son, Inc. Investor Conference on Genomics and Bioinformatics at the Essex House in New York City. The presentations are also being audio streamed over the Internet live. To hear the presentations, investors should go to informedinvestors.com to click through to the conference. The presentations will also be available archived after 24 hours. The full day's presentations begin at 8 a.m. EDT. The conference will provide invited institutional and venture capital investors with a detailed understanding of major trends in genetics and bioinformatics. Presentations by senior management of flagship public companies, as well as emerging private companies, will give conference attendees an overview of emerging technologies and the competitive landscape within the industry. Scheduled to present are: Dr. Bill Buffington, GM of Bioscience Products, Agilent Technologies, Inc. (NYSE: A); Dr. Peter Schad, CSO, AlphaGene Inc.; Dr. Sam Broder, Executive VP, Celera Genomics; Dr. Jonathon Rothberg, CEO, CuraGen Corp. (Nasdaq: CRGN); Dr. David Bailey, CEO, De Novo Pharmaceuticals; and Dr. Michael Brennan, CEO, Gene Logic Inc. (Nasdaq: GLGC). Also scheduled to present are: Steven Mayer, CFO, Human Genome Sciences; Roy Whitfield, CEO, Incyte Genomics; Dr. John Chiplin, CEO, GeneFormatics; Peter Meldrum, CEO, Myriad Genetics, Inc. (Nasdaq: MYGN); Cyrus Harmon, CFO, Neomorphic, Inc.; and Jim Lindelien, CEO, TimeLogic Corporation. Oscar Gruss & Son is a full service Investment and Merchant Bank, and a member of the NYSE, NASD and SIPC. As a specialty investment bank focusing on the healthcare and technology sectors, Oscar Gruss provides a range of investment research, sales and trading expertise in equities and specialty financial instruments, corporate finance and merchant banking. The company employs approximately 200 in its New York and Tel-Aviv offices. InformedInvestors.com is the leading producer of online and offline industry-specific investment conferences for individual investors and offers a growing stable of resources for in-depth sector-analysis including its two weekly radio shows, "Tech Check" and "BioTalk." SOURCE InformedInvestors.com CO: InformedInvestors.com; Celera Genomics; Human Genome Sciences; Incyte Genomics; Oscar Gruss & Son, Inc.; Agilent Technologies, Inc.; AlphaGene Inc.; CuraGen Corp.; De Novo Pharmaceuticals; Gene Logic Inc.; GeneFormatics; Myriad Genetics, Inc.; Neomorphic, Inc.; TimeLogic Corporation